On May 15, Iovance published robust interim data for the TIL therapy known as LN-145 and lifileucel for the treatment of advanced cervical cancer and advanced melanoma, respectively. More data will be presented at the 55th Annual Meeting of the American Society of Clinical Oncology ("ASCO") taking place May 31 to June 4, 2019, in Chicago. As the ongoing Phase 2 investigation, innovaTIL-04 assesses LN-145 in patients afflicted by cervical carcinoma. Keep in mind, these patients already had a mean of 2.6 different drugs. Remarkably, LN-145 exhibited the robust 44% Overall Response Rate ("ORR"). The aforesaid ORR was calculated by adding the one complete response rate ("CRR"), nine partial responses rate ("PRR"), and three unconfirmed partial responses rate ("UPR"). That aside, there was 89% disease control rate ("DCR") which is the equivalent of response rate plus stable disease. At the 3.5 months follow-up, nearly all (i.e. 11 out of 12) patients maintained a response.